表 2.7.4.4-3-1　バイタルサイン　脈拍数（02CLL III 試験）（続き）

Astellas Pharma GmbH, Germany / Sequence 0000

ribosepharm GmbH　　Bendamustine Hydrochloride versus Chlorambucil　　- Page 1925
Report　　in patients with B-CLL requiring therapy　　24/04/2007
Final Analysis

Table 20.5
Vital signs
Pulse [/min] - Summary statistics by visit and treatment

Safety Population

Visit / Summary statistics	BEN (A) (N = 154) Actual	BEN (A) (N = 154) Change	CLB (B) (N = 144) Actual	CLB (B) (N = 144) Change	Difference 1 B - A
Cycle 6					
n	92	85	75	73	
Mean (SD)	77.1 (8.3)	0.1 (11.1)	77.8 (7.5)	0.4 (9.5)	0.84 (7.30)
95% CL	[75.4; 78.8]	[-2.3; 2.5]	[76.1; 79.5]	[-1.8; 2.6]	[-1.46; 3.14]
Min-Max	60.0 - 104.0	-28.0 - 28.0	52.0 - 96.0	-28.0 - 22.0	F = 0.5186
Median	78.0	0.0	78.0	0.0	P = 0.4725
Q1-Q3	70.0 - 80.0	-7.0 - 8.0	72.0 - 82.0	-4.0 - 6.0	
Follow-up 1					
n	72	68	45	42	
Mean (SD)	76.4 (8.3)	-0.2 (10.8)	78.6 (8.3)	2.1 (7.3)	2.62 (7.49)
95% CL	[74.4; 78.3]	[-2.8; 2.4]	[76.1; 81.1]	[-0.1; 4.4]	[-0.30; 5.53]
Min-Max	52.0 - 108.0	-32.0 - 20.0	56.0 - 100.0	-17.0 - 20.0	F = 3.1719
Median	76.5	0.0	80.0	4.0	P = 0.0778
Q1-Q3	71.0 - 80.0	-5.5 - 8.0	72.0 - 84.0	-1.0 - 7.0	
Follow-up 2					
n	54	50	21	21	
Mean (SD)	75.5 (8.2)	-2.2 (9.7)	77.6 (7.7)	0.2 (8.5)	2.17 (7.29)
95% CL	[73.2; 77.7]	[-4.9; 0.6]	[74.1; 81.1]	[-3.7; 4.0]	[-1.61; 5.96]
Min-Max	57.0 - 92.0	-30.0 - 18.0	64.0 - 92.0	-20.0 - 18.0	F = 1.3108
Median	76.0	-1.5	78.0	0.0	P = 0.2563
Q1-Q3	70.0 - 80.0	-7.0 - 4.0	72.0 - 84.0	-4.0 - 4.0	
Follow-up 3					
n	39	37	11	11	
Mean (SD)	74.1 (8.2)	-3.2 (11.0)	81.1 (10.5)	0.4 (12.1)	5.78 (8.24)
95% CL	[71.4; 76.8]	[-6.8; 0.5]	[74.0; 88.2]	[-7.8; 8.5]	[0.03; 11.52]
Min-Max	59.0 - 92.0	-30.0 - 24.0	68.0 - 108.0	-22.0 - 28.0	F = 4.0995
Median	72.0	-4.0	80.0	0.0	P = 0.0489
Q1-Q3	68.0 - 80.0	-8.0 - 2.0	76.0 - 85.0	-4.0 - 6.0	
Follow-up 4					
n	34	30	5	5	
Mean (SD)	77.0 (7.9)	-1.0 (11.9)	81.6 (9.5)	6.4 (8.5)	5.02 (7.72)
95% CL	[74.2; 79.8]	[-5.5; 3.5]	[69.8; 93.4]	[-4.2; 17.0]	[-2.61; 12.65]
Min-Max	64.0 - 96.0	-30.0 - 28.0	72.0 - 92.0	-8.0 - 14.0	F = 1.7958
Median	77.0	1.0	82.0	10.0	P = 0.1897
Q1-Q3	70.0 - 80.0	-8.0 - 4.0	72.0 - 90.0	6.0 - 10.0	

Baseline=Cycle 1/Day 1 if data at screening examination not available
For change from baseline only patients with pairewise available visits are considered
Differences between groups and 95% confidence limits are adjusted for baseline values
(Least square means from analysis of variance)
Data after follow-up 4 are not displayed

d.s.h. statistical services gmbh

Ribomustin Test 1 MS/ 5.3.5.1.1 CLL Mundipharma 02CLLIII-ID900 /p10856

引用:CSR Appendix14 Table20.5

表 2.7.4.4-3-2　バイタルサイン 脈拍数（02CLL III FU）

Visit	BEN (A) (N = 161			CLB (B) (N = 151)			Difference [1] B – A [95% CI]
	N	Actual	Change	N	Actual	Change	
Baseline	149	77.6 (10.3)		136	77.9 (9.1)		
Cycle 2	128	75.4 (8.6)	-1.7 (9.2)	127	78.4 (8.7)	0.5 (9.3)	2.82 (7.28) [0.96; 4.68]
Cycle 3	116	77.0 (9.2)	-0.0 (10.8)	119	77.0 (8.5)	-0.2 (8.8)	-0.02 (8.03) [-2.15; 2.11]
Cycle 4	115	76.1 (8.1)	-0.9 (11.8)	106	76.6 (8.5)	-0.0 (9.0)	0.86 (7.88) [-1.29; 3.01]
Cycle 5	109	74.8 (8.7)	-2.8 (11.4)	92	76.8 (8.3)	-0.3 (8.6)	2.54 (7.55) [0.37; 4.72]
Cycle 6	98	77.1 (8.1)	0.0 (10.8)	81	77.1 (8.1)	0.0 (10.8)	0.76 (7.21) [-1.44; 2.96]

引用: 02CLL III FU　Table 77

表 2.7.4.2.2-4-1　バイタルサイン 体温（02CLLⅢ試験）

ribosepharm GmbH　　Bendamustine Hydrochloride versus Chlorambucil　　- Page 1926
Report　　in patients with B-CLL requiring therapy　　24/04/2007
Final Analysis

Table 20.6
Vital signs
Temperature [°C] - Summary statistics by visit and treatment

Safety Population

Visit / Summary statistics	BEN (A) (N = 154) Actual	BEN (A) (N = 154) Change	CLB (B) (N = 144) Actual	CLB (B) (N = 144) Change	Difference [1] B - A
Baseline					
n	125		118		
Mean (SD)	36.6 (0.5)		36.6 (0.5)		
95% CL	[36.6; 36.7]		[36.5; 36.7]		
Min-Max	35.2 - 39.0		33.9 - 38.0		
Median	36.6		36.6		
Q1-Q3	36.4 - 36.9		36.4 - 36.8		
Cycle 2					
n	113	103	112	101	
Mean (SD)	36.6 (0.5)	-0.1 (0.5)	36.5 (0.4)	-0.1 (0.5)	0.01 (0.36)
95% CL	[36.5; 36.7]	[-0.2; -0.0]	[36.5; 36.6]	[-0.2; 0.0]	[-0.08; 0.11]
Min-Max	34.6 - 38.5	-2.2 - 0.9	35.3 - 38.2	-1.3 - 2.1	F = 0.0740
Median	36.6	0.0	36.6	0.0	P = 0.7858
Q1-Q3	36.4 - 36.8	-0.3 - 0.2	36.2 - 36.8	-0.3 - 0.2	
Cycle 3					
n	108	97	108	97	
Mean (SD)	36.5 (0.5)	-0.2 (0.5)	36.5 (0.4)	-0.1 (0.4)	0.01 (0.35)
95% CL	[36.4; 36.6]	[-0.3; -0.0]	[36.4; 36.6]	[-0.1; 0.0]	[-0.09; 0.11]
Min-Max	34.5 - 39.0	-2.6 - 1.0	34.6 - 37.2	-1.8 - 0.8	F = 0.0313
Median	36.6	0.0	36.5	0.0	P = 0.8598
Q1-Q3	36.3 - 36.8	-0.3 - 0.1	36.3 - 36.8	-0.2 - 0.2	
Cycle 4					
n	100	91	93	84	
Mean (SD)	36.6 (0.4)	-0.1 (0.5)	36.5 (0.3)	-0.1 (0.4)	0.03 (0.31)
95% CL	[36.5; 36.6]	[-0.2; -0.0]	[36.5; 36.6]	[-0.2; 0.0]	[-0.07; 0.12]
Min-Max	35.5 - 38.8	-2.2 - 1.5	35.8 - 37.5	-1.8 - 1.2	F = 0.2828
Median	36.6	0.0	36.5	0.0	P = 0.5955
Q1-Q3	36.4 - 36.8	-0.4 - 0.1	36.3 - 36.7	-0.3 - 0.2	
Cycle 5					
n	96	86	75	70	
Mean (SD)	36.5 (0.4)	-0.2 (0.6)	36.5 (0.4)	-0.1 (0.5)	-0.00 (0.40)
95% CL	[36.4; 36.6]	[-0.3; -0.1]	[36.4; 36.6]	[-0.2; -0.0]	[-0.13; 0.13]
Min-Max	35.2 - 38.6	-2.2 - 2.7	35.1 - 37.6	-1.6 - 1.0	F = 0.0016
Median	36.5	-0.1	36.5	-0.1	P = 0.9677
Q1-Q3	36.3 - 36.7	-0.4 - 0.1	36.2 - 36.7	-0.4 - 0.2	

Baseline=Cycle 1/Day 1 if data at screening examination not available
For change from baseline only patients with pairwise available visits are considered
Differences between groups and 95% confidence limits are adjusted for baseline values
(Least square means from analysis of variance)
Data after follow-up 4 are not displayed

d.s.h. statistical services gmbh

Ribomustin Test 1 MS/ 5.3.5.1.1 CLL Mundipharma 02CLLIII-ID900 /p10857

引用:CSR Appendix14 Table20.6